Abstract

A 72-year-old Japanese woman who had been suffering from rheumatoid arthritis for five years started treatment with infliximab. The screening of a chest X-ray before initiating infliximab treatment showed no abnormal shadows. After a month of infliximab, she was admitted to the emergency hospital with a half-month history of a fever, fatigue, dyspnea, and cough. She was diagnosed with tuberculosis from a culture smear and referred to our hospital. The chest images showed a bilateral massive cavity and infiltration. Despite the administration of an anti-tuberculous agent, the cavity and infiltration were enlarged on a chest X-ray and the patient died due to respiratory failure. Cases of tuberculosis resulting in death after a short duration of infliximab treatment have been rarely reported. We speculate that chest CT and the interferon-gamma release assay (IGRA) for tuberculosis screening should be evaluated before starting infliximab treatment, and preventive administration of isoniazid should be considered with consultation with a pulmonologist.

Highlights

  • Tuberculosis remains one of the major causes of death worldwide [1]

  • We reported a case of Rheumatoid arthritis (RA) who developed tuberculosis after infliximab treatment

  • Infliximab is antagonist of TNF-α and has been used for the treatment of RA, Crohn’s disease, psoriasis vulgaris, and Behcet’s disease. This agent has been demonstrated to reduce the symptoms of such diseases, it can lead to an increased incidence of infections, including mycobacterium infection

Read more

Summary

Open Access

Fulminant Pulmonary Tuberculosis by Infliximab in Patient with Rheumatoid Arthritis. Received date: Oct 16, 2015; Accepted date: Apr 16, 2016; Published date:Apr 23, 2016

Introduction
Serology CRP
Findings
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call